期刊文献+

度洛西汀与氟西汀改善躯体形式障碍患者症状及社会功能效果的对照研究 被引量:19

A comparative study of duloxetine vs. fluoxetine for improving symptoms and social function of patients with somatoform disorder
下载PDF
导出
摘要 目的探讨度洛西汀与氟西汀对改善躯体形式障碍患者症状及社会功能的效果。方法将134例躯体形式障碍患者随机分为研究组(度洛西汀系统治疗)和对照组(氟西汀系统治疗),共治疗8周。在基线及治疗后第1、2、4、8周末采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、社会功能缺陷量表(SDSS)及治疗中需处理的不良反应症状量表(TESS)评定疗效及不良反应。结果研究组患者在治疗后第1周末起HAMD及HAMA量表评分均显著低于基线时(P<0.05),而对照组治疗后第2周末起HAMD及HAMA量表评分均显著低于基线时(P<0.05);治疗后第1、2、4、8周末研究组HAMD及HAMA量表评分均低于对照组(P<0.05)。研究组治疗后第4周末起SDSS量表评分显著低于基线时(P<0.05),而对照组治疗后第8周末SDSS量表评分显著低于基线时(P<0.05)。治疗后第4、8周末研究组SDSS量表评分均低于对照组(P<0.05)。两组均未出现严重不良反应。结论度洛西汀可有效、快速的改善躯体形式障碍患者的抑郁、焦虑症状及社会功能,效果优于氟西汀。 Objective To explore the efficacy of duloxetine vs.fluoxetine for improving symptoms and social function of patients with somatoform disorder.Methods 134 patients with somatoform disorder were randomly divided into study group treated with duloxetine and control group treated with fluoxetine for 8 weeks.They were assessed with Hamilton Depression Scale (HAMD),Hamilton Anxiety Scale (HAMA),Social Disability Screening Schedule (SDSS) and Treatment Emergent Side Effect Scale (TESS) at baseline and at the end of the 1st,2nd,4th and 8th week to evaluate the efficacy and side effects.Results Compared with baseline,scores of HAMD and HAMA in study group decreased significantly at the end of the 1 st week (P <0.05),while in control group the significance appeared till at the end of the 2nd week (P < 0.05).Scores of HAMD and HAMA in study group at the end of 1st,2nd,4th,8th week were significantly lower than those in control group (P <0.05).Score of SDSS at the end of the 4th week in study group was significantly lower than that at baseline (P < 0.05),while the significance appeared till at the end of the 8th week in control group (P < 0.05).Scores of SDSS at the end of the 4th and 8th week in study group were significantly lower than those in control group (P < 0.05).There was no severe side effects in both groups.Conclusion Duloxetine is effective in improving anxiety,depressive symptoms and social function of patients with somatoform disorder.Moreover,it takes effect rapidly.The efficacy of duloxetine is better than that of fluoxetine.
作者 贺津 高勇
出处 《精神医学杂志》 2014年第2期120-122,共3页 Journal of Psychiatry
关键词 度洛西汀 氟西汀 躯体形式障碍 社会功能 Duloxetine Fluoxetine Somatoform disorder Social function
  • 相关文献

参考文献21

二级参考文献138

共引文献719

同被引文献138

  • 1苏晖,江开达,徐一峰,宋立升,虞一萍.抑郁症首次发病患者治疗前后认知功能的研究[J].中华精神科杂志,2006,39(1):20-23. 被引量:53
  • 2陈巧珍,李惠春.躯体形式障碍的优化诊治[J].医学与哲学(B),2006,27(8):38-39. 被引量:3
  • 3骆艳丽,吴文源,李春波,张明园.医学结局研究用疼痛量表在腰痛患者中的信效度初步研究[J].中国心理卫生杂志,2006,20(11):713-715. 被引量:75
  • 4张朝辉,张亚林,陈佐明,宋景贵.躯体化障碍临床特征的研究[J].新乡医学院学报,2007,24(6):579-580. 被引量:22
  • 5沈渔一.精神病学[M].5版.北京:人民卫生出版社,2009:657-658.
  • 6王辉,侯红波,谷旦华.艾司西酞普兰与氟西汀治疗躯体形式障碍疗效及安全性对比研究[J].中外健康文摘,2013,3(10):234-235.
  • 7Kleins~ M, Witthoft M, Steffmaowski A, et al. Pharmacological interventions for somatoform disorders in adults [ J ]. Cochrane Database Syst Rev, 2014, 11 :CD010628.
  • 8Pollatos O, Dietel A, Herbert BM, et al. Blunted autonomic reactivity and increased pain tolerance in somatoform patients [J]. Pain, 2011, 152(9) : 2157 -2164.
  • 9Pollatos O, Herbert BM, Wankner S, et al. Autonomic imbalance is associated with reduced facial recognition in somatoform disorders [ J ]. J Psychosom Res, 2011,71 (4) : 232 - 239.
  • 10Barakat A, Vogelzangs N, Licht CM, et al. Dysregulation of the autonomic nervous system and its association with the presence and intensity of chronic widespread pain [ J ]. Arthritis Care Res (Hoboken), 2012, 64(8) : 1209 -1216.

引证文献19

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部